| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-10-17 | Gemini therapeutics (USA - MA) | $42.5 Million | series A financing round | Atlas Venture (USA-MA) Lightstone Ventures (USA-CA) OrbiMed (USA-NY) | Rare diseases - Genetic diseases- Ophthalmological diseases | Series A financing round |
| 2017-10-13 | InflaRX (Germany) | $ 55 million | series D financing round | Bain Capital Life Sciences (USA) Cormorant Asset Management (USA) RA Capital Management (USA) undisclosed investment funds managed by a leading US investment management firm | Inflammatory diseases | Series D financing round |
| 2017-10-09 | Faron Pharmaceuticals (Finland) | £10.0 million | private placement | Cardiovascular diseases | Private placement | |
| 2017-10-02 | KSQ Therapeutics (USA - MA) | $76 million | financing round | Flagship Pioneering (USA - MA) Polaris Partners (USA - MA) ARCH Venture Partners (USA - IL) Alexandria Equities (USA - CA) | Cancer - Oncology - Immunological diseases | Financing round |
| 2017-09-26 | Juno Therapeutics (USA - WA) | $318.7 million | private placement | Cancer - Oncology | Private placement | |
| 2017-09-25 | Deep Genomics (Canada) | $13 million | financing round | Khosla Ventures (USA - CA) True Ventures (USA - CA) | Technology - Services | Financing round |
| 2017-09-25 | eTheRNA immunotherapies (Belgium) | €1 million | grant | Flanders Innovation & Entrepreneurship (VLAIO) (Belgium) | Cancer - Oncology | Grant |
| 2017-09-25 | Iovance Biotherapeutics (USA - CA) | $57.5 million. | private placement | Cancer - Oncology | Private placement | |
| 2017-09-22 | DaVolterra (France) | € 20 million | loan | European Investment Bank (EIB) | Infectious diseases | Loan |
| 2017-09-22 | Krystal Biotech (USA - PA) | $45,54 million | IPO | Dermatological diseases | IPO | |
| 2017-09-19 | Epizyme (USA - MA) | $151.3 million | private placement | Cancer - Oncology | Private placement | |
| 2017-09-18 | Evotec (Germany) | up to € 75 million | loan | European Investment Bank (EIB) | Technology - Services | Loan |
| 2017-09-18 | Soligenix (USA - NJ) | $1.5 million | grant | National Cancer Institute (NCI) (USA) | Cancer - Oncology | Grant |
| 2017-09-13 | Genenta Science (Italy) | $8,4 Million (€7 Million) | series B financing round | Italian, British, and Swiss private investors, family offices, business angels, Banca Esperia (Italy) Mediolanum (Italy), board members | Cancer - Oncology | Series B financing round |
| 2017-09-11 | IGEM Therapeutics (UK) | £2 million | series A financing round | Epidarex Capital (UK) | Cancer - Oncology | Series A financing round |
| 2017-09-11 | Amphivena Therapeutics (USA - CA) | series B financing round | Tekla Capital Management (USA - MA) | Cancer - Oncology - Rare diseases | Series B financing round | |
| 2017-08-28 | Apeiron Biologics (Austria) | € 25 million | grant | European Investment Bank (EIB) | Cancer - Oncology | Grant |
| 2017-08-15 | Omeros (USA - Wn) | private placement | Private placement | |||
| 2017-08-15 | Dynavax (USA - CA) | $80.8 million | private placement | Infectious diseases | Private placement | |
| 2017-08-09 | Spark Therapeutics (USA - PA) | $380.4 million | private placement | Private placement |
